Home Federal Bank of Tennessee grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,605 shares of the company’s stock after buying an additional 505 shares during the quarter. Home Federal Bank of Tennessee’s holdings in Merck & Co., Inc. were worth $1,207,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Sowa Financial Group Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Total Clarity Wealth Management Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Stephenson National Bank & Trust bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $28,000. CBIZ Investment Advisory Services LLC raised its holdings in shares of Merck & Co., Inc. by 180.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock worth $32,000 after purchasing an additional 271 shares during the period. Finally, Lion Street Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter worth approximately $35,000. 74.33% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total transaction of $380,100.00. Following the completion of the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $387,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.28% of the stock is owned by insiders.
A number of equities research analysts recently commented on the stock. Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a report on Monday, May 4th. Barclays lowered their price target on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Royal Bank of Canada lowered their price target on shares of Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating on the stock in a report on Wednesday, April 1st. Argus lowered their price target on shares of Merck & Co., Inc. from $105.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Finally, SVB Leerink lowered their target price on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, April 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $94.15.
Shares of MRK traded down $1.02 during mid-day trading on Wednesday, reaching $77.70. 4,152,740 shares of the stock traded hands, compared to its average volume of 10,337,286. The firm has a fifty day moving average price of $78.23 and a 200 day moving average price of $81.49. The company has a market cap of $198.57 billion, a price-to-earnings ratio of 19.92, a price-to-earnings-growth ratio of 2.22 and a beta of 0.48. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $92.64.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.16. The firm had revenue of $12.06 billion during the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.22 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 5.3 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th were given a dividend of $0.61 per share. The ex-dividend date was Friday, June 12th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.14%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.01%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Read More: Reverse Stock Split
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.